Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 26CNS 4Gastrointestinal 3Tumor-Agnostic 2Head & Neck 1

Conditions

Adenocarcinoma 2

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × icotinib × Tumor-Agnostic × Clear all
NCT02125240 2018-07-16

ICWIP

Betta Pharmaceuticals Co., Ltd.

Phase 3 Unknown
124 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT02103257 2015-04-29

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
192 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡